International Journal of Clinical Pharmacy

, Volume 40, Issue 3, pp 650–658 | Cite as

Pharmacist supply of sildenafil: pharmacists’ experiences and perceptions on training and tools for supply

  • Rhiannon BraundEmail author
  • Kaushalya Ratnayake
  • Katie Tong
  • Jackie Song
  • Stephen Chai
  • Natalie Gauld
Research Article


Background In 2014, New Zealand reclassified sildenafil (for erectile dysfunction) to allow supply by specially trained pharmacists under strict criteria. Objective The study aimed to determine pharmacists’ experiences and perspectives on the training for, and supply of sildenafil under this model. Setting New Zealand community pharmacy. Method This qualitative study captured data with a semi-structured interview used with purposively-sampled participants. A maximum variation sample was used to select a wide range of pharmacists working in various pharmacies, including pharmacists who were trained to provide sildenafil and those not trained to supply sildenafil. Consenting pharmacists were interviewed, with interviews audio-recorded and transcribed. Analysis used a framework approach. Main outcome measures Topics explored included: satisfaction and experience of the training; suitability and usability of the screening tools; experiences of the supply process and why some pharmacists chose not to become trained. Results Thirty-five pharmacists were interviewed. Training was seen as uncomplicated and the screening tools provided confidence that key consultation areas were covered. Most consultations reportedly took 15–20 min, some up to 60 min. Pharmacists reported being comfortable with the consultations. Many men requesting supply fell outside of the parameters, resulting in medical referral. This new model of supply was seen as a positive for pharmacists and their patients. Unaccredited pharmacists reported a perceived lack of interest from men, or ability to provide the service as reasons for not seeking accreditation. Conclusion New Zealand’s model of pharmacist supply of sildenafil appears workable with some areas for improvement identified.


Community pharmacy services Erectile dysfunction New Zealand Pharmacist’s training Reclassification Sildenafil 


Conflicts of interest

NG works on widening access to medicines through reclassification, and has consulted to industry on reclassification of erectile dysfunction medicines, including receiving consulting fees from Douglas Pharmaceuticals for the reclassification of sildenafil in New Zealand. The rest of the authors have nothing to declare.

Supplementary material

11096_2018_622_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 14 kb)


  1. 1.
    Gauld NJ, Kelly FS, Kurosawa N, Bryant LJM, Emmerton LM, Buetow SA. Widening consumer access to medicines through switching medicines to non-prescription: a six country comparison. PLoS ONE. 2014;9(9):e107726.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med. 2001;345(11):810–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Bradley C, Blenkinsopp A. Over the counter drugs: the future for self medication. BMJ. 1996;312(7034):835–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gauld N. Why the resurgence of OTC reclassifications in the UK is a good thing. Clin Pharm. 2017. Scholar
  5. 5.
    Ahmed S, Rutter PM. UK community pharmacists experiences on over-the-counter tamsulosin. SelfCare. 2011;2(6):152–9.Google Scholar
  6. 6.
    Mann S. Simvastatin for self-medication in the UK. SelfCare J. 2010;1(1):29–43.Google Scholar
  7. 7.
    Wilkes D. Merck & Co deal boosts Bayer but Oxytrol goes. OTC Toolbox 2015.Google Scholar
  8. 8.
    Paudyal V, Hansford D, Cunningham S, Stewart D. Over-the-counter prescribing and pharmacists’ adoption of new medicines: diffusion of innovations. Res Social Adm Pharm. 2013;9(3):251–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Editorial. Over-the-counter triptans–making the switch. Lancet Neurol. 2005;4(10):587.Google Scholar
  10. 10.
    NIH Consensus Conference. Impotence. J Am Med Assoc. 1993;270(1):83–90.CrossRefGoogle Scholar
  11. 11.
    Rubin N, Wylie K. Should sildenafil be available over the counter? Br Med Bull. 2009;90:53–62.CrossRefPubMedGoogle Scholar
  12. 12.
    Tsertsvadze A, Yazdi F, Fink HA, MacDonald R, Wilt TJ, Soares-Weiser K, et al. Diagnosis and treatment of erectile dysfunction. Ottawa: University of Ottawa Evidence-based Practice Center; 2009.Google Scholar
  13. 13.
    Paige NM, Hays RD, Litwin MS, Rajfer J, Shapiro MF. Improvement in emotional well-being and relationships of users of sildenafil. J Urol. 2001;166(5):1774–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7(4 Pt 2):1598–607.CrossRefPubMedGoogle Scholar
  15. 15.
    Levine GN, Steinke EE, Bakaeen FG, Bozkurt B, Cheitlin MD. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2012;125:1058–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Jannini EA, Sternbach N, Limoncin E, Ciocca G, Gravina GL, Tripodi F, et al. Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European Countries. J Sex Med. 2014;11(1):40–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Morales AM, Ibanez J, Machuca M, Pol-Yanguas E, Schnetzler G, Renedo VP. The EPIFARM study: an observational study in 574 community pharmacies in Spain characterizing patient profiles of men asking for erectile dysfunction medication. J Sex Med. 2010;7(9):3153–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Shaeer O. The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers. J Sex Med. 2013;10(2):532–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Jackson G, Arver S, Banks I, Stecher VJ. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks. Int J Clin Pract. 2010;64(4):497–504.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Nicolosi A, Buvat J, Glasser DB, Hartmann U, Laumann E, Gingell C. Sexual behavior, sexual dysfunction and related help seeking patterns in middle-aged and elderly Europeans: the global study of sexual attitudes and behaviors. World J Urol. 2006;24:423–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Chew KK, Stuckey B, Bremner A, Earle C, Jamrozik K. Male erectile dysfunction: its prevalence in Western Australia and associated sociodemographic factors. J Sex Med. 2008;5(1):60–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Colson MH, Roussey G. Screening and managing erectile dysfunction in diabetic patients (review). Sexologies. 2013;22(1):e1–8.CrossRefGoogle Scholar
  24. 24.
    Classification of Medicines. New Zealand Gazette. 2014;2014-go6426(127):3556.Google Scholar
  25. 25.
    Protocol for the sale and supply of pharmacist only medicines for chronic conditions. Pharmacy Council of New Zealand. Accessed 11 May 2016.
  26. 26.
    International Pharmaceutical Federation (FIP). An overview of current pharmacy impact on immunisation a global report 2016. The Hague: International Pharmaceutical Federation; 2016.Google Scholar
  27. 27.
    Yang YT, Kozhimannil KB, Snowdon JM. Pharmacist-prescribed birth control in Oregon and other states. JAMA. 2016;315:1567–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Nissen L, Glass B, Lau E, Rosenthal M. Queensland pharmacist immunisation pilot phase 1 pharmacist vaccination—influenza final report 2015.
  29. 29.
    Gardner JS, Miller L, Downing DF, Le S, Blough DK, Shotorbani S. Pharmacist prescribing of hormonal contraceptives: results of the direct access study. J Am Pharm Assoc. 2008;48:212–26.CrossRefGoogle Scholar
  30. 30.
    Parsons J, Adams C, Aziz N, Holmes J, Jawad R, Whittlesea C. Evaluation of a community pharmacy delivered oral contraception service. J Fam Plan Reprod Health Care. 2013;39(2):97–101.CrossRefGoogle Scholar
  31. 31.
    Braund R, Henderson E, McNab E, Sarten R, Wallace E, Gauld N. Pharmacist-only trimethoprim: pharmacist satisfaction on their training and the impact on their practice. Int J Clin Pharm. 2016;38(6):1357–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Gauld NJ, Zeng ISL, Ikram RB, Thomas MG, Buetow SA. Antibiotic treatment of women with uncomplicated cystitis before and after allowing pharmacist-supply of trimethoprim. Int J Clin Pharm. 2017;39(1):165–72.CrossRefPubMedGoogle Scholar
  33. 33.
    Paudyal V, Hansford D, Cunningham S, Stewart D. Community pharmacists’ adoption of medicines reclassified from prescription-only status: a systematic review of factors associated with decision making. Pharmacoepidemiol Drug Saf. 2012;21(4):396–406.CrossRefPubMedGoogle Scholar
  34. 34.
    Paudyal V, Hansford D, Cunningham S, Stewart D. Pharmacists’ perceived integration into practice of over-the-counter simvastatin five years post reclassification. Int J Clin Pharm. 2012;34(5):733–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Patton MQ. Qualitative research and evaluation methods. 3rd ed. London: Sage Publications; 2002.Google Scholar
  36. 36.
    Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ. 2000;320(7227):114–6.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Gauld N, Kelly F, Shaw J. Is non-prescription oseltamivir availability under strict criteria workable? A qualitative study in New Zealand. J Antimicrob Chemother. 2011;66(1):201–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Gauld NJ, Jennings LC, Frampton C, Huang QS. Five years of non-prescription oseltamivir: effects on resistance, immunization and stock-piling. J Antimicrob Chemother. 2012;67:2949–56.CrossRefPubMedGoogle Scholar
  39. 39.
    Hattingh HL, Sim TF, Parsons R, Czarniak P, Vickery A, Ayadurai S. Evaluation of the first pharmacist-administered vaccinations in Western Australia: a mixed-methods study. BMJ Open. 2016. Scholar
  40. 40.
    Dunn S, Brown TER, Alldred J. Availability of emergency contraception after its deregulation from prescription-only status: a survey of Ontario pharmacies. CMAJ. 2008;178(4):423–4.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Symonds T, Dean JD, Carr A, Carlsson M, Marfatia A, Schnetzler G. A feasibility study comparing pharmacist and physician recommendations for sildenafil treatment. J Sex Med. 2011;8(5):1463–71.CrossRefPubMedGoogle Scholar
  42. 42.
    Schneider CR, Gudka S, Fleischer L, Clifford RM. The use of a written assessment checklist for the provision of emergency contraception via community pharmacies: a simulated patient study. Pharm Pract. 2013;11(3):127–31.CrossRefGoogle Scholar
  43. 43.
    Edwards N, Gorman Corsten E, Kiberd M, Bowles S, Isenor J, Slayter K, et al. Pharmacists as immunizers: a survey of community pharmacists’ willingness to administer adult immunizations. Int J Clin Pharm. 2015;37(2):292–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Kirby M, Phillips G, Carr A. Professional competence of pharmacists in recommending Flomax Relief MR (tamsulosin) to men with lower urinary tract symptoms. Pharm J Online. 2011:1–5.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of OtagoDunedinNew Zealand
  2. 2.University of AucklandAucklandNew Zealand

Personalised recommendations